

Dapagliflozin: DAPA-CKD Trial

Table of Contents

The table of contents is organized into two main sections: 'DAPA-CKD Trial' and 'DAPA-CKD in Context'. The 'DAPA-CKD Trial' section is further divided into 'Unmet Need and Study Introduction', 'Study Design', and 'Results'. The 'Results' section is subdivided into 'Baseline Characteristics', 'Primary Endpoint', 'Secondary Endpoints', 'Additional Endpoints', 'Safety', and 'Additional Analyses'. The 'DAPA-CKD in Context' section is divided into 'Summary of Dapagliflozin Use in CKD' and 'Key Renal Outcome Trials'. The 'Additional Analyses' box is highlighted in a darker purple color.

DAPA-CKD Trial					
Unmet Need and Study Introduction			Study Design		
Results					
Baseline Characteristics	Primary Endpoint	Secondary Endpoints	Additional Endpoints	Safety	Additional Analyses
DAPA-CKD in Context					
Summary of Dapagliflozin Use in CKD			Key Renal Outcome Trials		



Table of Contents – Additional Analyses

DIABETES ANALYSES

- T2D Status
- Glycemic Status (HbA1c)
- New Onset T2D

GENERAL ANALYSES

- Cause of Mortality
- Geographic Regions
- BMI Category

CV ANALYSES

- Baseline HF History
- Baseline CVD Status
- Baseline PAD
- Baseline AF

CKD-RELATED ANALYSES

BACKGROUND THERAPY

- CV Medication

CKD ETIOLOGY

- General
- IgA Nephropathy
- FSGS

CKD CHARACTERISTICS

- Effect on eGFR
- Effect on Albuminuria
- Stage 4 CKD
- Baseline Albuminuria